Pyridine nucleotide redox abnormalities in diabetes

Antioxidants and Redox Signaling

Volumn 9, Issue 7, 2007, Pages 931-942

  Ido, Yasuo ^a,b  

^a BOSTON UNIVERSITY MEDICAL CENTER   (United States)

^b BOSTON MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALDEHYDE REDUCTASE; BINDING PROTEIN; BRANCHED CHAIN AMINO ACID; DIACYLGLYCEROL; FATTY ACID; GENE PRODUCT; GLUCOSE; GLYCERALDEHYDE 3 PHOSPHATE DEHYDROGENASE; IDITOL DEHYDROGENASE; LACTIC ACID; METHYLGLYOXAL; NICOTINAMIDE ADENINE DINUCLEOTIDE; POLYOL; PROTEIN SIRT1; PYRIDINE NUCLEOTIDE; REACTIVE OXYGEN METABOLITE; REDUCED NICOTINAMIDE ADENINE DINUCLEOTIDE; SORBITOL; UNCLASSIFIED DRUG;

APOPTOSIS; CARBOXY TERMINAL SEQUENCE; CYTOSOL; DIABETES MELLITUS; DIABETIC NEUROPATHY; ENZYME INHIBITION; GENE EXPRESSION; GENETIC TRANSCRIPTION; HUMAN; HYPERGLYCEMIA; LONGEVITY; MITOCHONDRION; NONHUMAN; OXIDATION REDUCTION REACTION; PATHOGENESIS; PRIORITY JOURNAL; REDUCTIVE STRESS; REVIEW; SIGNAL TRANSDUCTION; STRESS; SYSTEMATIC REVIEW;

ANIMALS; CYTOSOL; DIABETES MELLITUS; GLYCERALDEHYDE-3-PHOSPHATE DEHYDROGENASE (PHOSPHORYLATING); HUMANS; MITOCHONDRIA; MODELS, BIOLOGICAL; NAD; OXIDATION-REDUCTION; OXIDATIVE STRESS;

EID: 34250355194     PISSN: 15230864     EISSN: None     Source Type: Journal    
DOI: 10.1089/ars.2007.1630     Document Type: Review

References (133)

1. Adachi T, Weisbrod RM, Pimentel DR, Ying J, Sharov VS, Schoneich C, and Cohen RA. S-Glutathiolation by peroxynitrite activates SERCA during arterial relaxation by nitric oxide. Nat Med 10: 1200-1207, 2004.
2. Amano S, Yamagishi S, Kato N, Inagaki Y, Okamoto T, Makino M, Taniko K, Hirooka H, Jomori T, and Takeuchi M. Sorbitol dehydrogenase overexpression potentiates glucose toxicity to cultured retinal pericytes. Biochem Biophys Res Commun 299: 183-188, 2002.
3. Avogaro A, Crepaldi C, Miola M, Maran A, Pengo V, Tiengo A, and Del Prato S. High blood ketone body concentration in type 2 non-insulin dependent diabetic patients. J Endocrinol Invest 19: 99-105, 1996.
4. Avogaro A, Toffolo G, Miola M, Valerio A, Tiengo A, Cobelli C, and Del Prato S. Intracellular lactate- and pyruvate-interconversion rates are increased in muscle tissue of non-insulin-dependent diabetic individuals. J Clin Invest 98: 108-115, 1996.
5. Bach D, Naon D, Pich S, Soriano FX, Vega N, Rieusset J, Laville M, Guillet C, Boirie Y, Wallberg-Henriksson H, Manco M, Calvani M, Castagneto M, Palacin M, Mingrone G, Zierath JR, Vidal H, and Zorzano A. Expression of Mfn2, the Charcot-Marie-Tooth neuropathy type 2A gene, in human skeletal muscle: effects of type 2 diabetes, obesity, weight loss, and the regulatory role of tumor necrosis factor {alpha} and interleukin-6. Diabetes 54: 2685-2693, 2005.
6. Baur JA, Pearson KJ, Price NL, Jamieson HA, Lerin C, Kalra A, Prabhu VV, Allard JS, Lopez-Lluch G, Lewis K, Pistell PJ, Poosala S, Becker KG, Boss O, Gwinn D, Wang M, Ramaswamy S, Fishbein KW, Spencer RG, Lakatta EG, Le Couteur D, Shaw RJ, Navas P, Puigserver P, Ingram DK, de Cabo R, and Sinclair DA. Resveratrol improves health and survival of mice on a high-calorie diet. Nature 444: 337-342, 2006.
7. Befroy DE, Falk Petersen K, Dufour S, Mason GF, de Graaf RA, Rothman DL, and Shulman GI. Impaired mitochondrial substrate oxidation in muscle of insulin-resistant offspring of type 2 diabetic patients. Diabetes db06-0783, 2007.
8. Beisswenger PJ, Howell SK, Smith K, and Szwergold BS. Glyceraldehyde-3-phosphate dehydrogenase activity as an independent modifier of methylglyoxal levels in diabetes. Biochim Biophys Acta 1637: 98-106, 2003.
9. Bergman LM and Blaydes JR C-terminal binding proteins: emerging roles in cell survival and tumorigenesis. Apoptosis V11:879-888, 2006.
10. Berry GT, Wehrli S, Reynolds R, Palmieri M, Frangos M, Williamson JR, and Segal S. Elevation of erythrocyte redox potential linked to galactonate biosynthesis: elimination by Tolrestat. Metabolism 47: 1423-1428, 1998.
11. Boden G. Effects of free fatty acids (FFA) on glucose metabolism: significance for insulin resistance and type 2 diabetes. Exp Clin Endocrinol Diabetes 111: 121-124, 2003.
12. Bremer J and Davis EJ. Citrate as a regulator of acetyl-CoA metabolism in liver mitochondria. Biochim Biophys Acta 370: 564-572, 1974.
13. Bremer J and Davis EJ. Studies on the active transfer of reducing equivalents into mitochondria via the malate-aspartate shuttle. Biochim Biophys Acta 376: 387-397, 1975.
14. Bril V and Buchanan RA. Long-term effects of ranirestat (AS-3201) on peripheral nerve function in patients with diabetic sensorimotor polyneuropathy. Diabetes Care 29: 68-72, 2006.
15. Brownlee M. Biochemistry and molecular cell biology of diabetic complications. Nature 414: 813-820, 2001.
16. Bucher T, Brauser B, Conze A, Klein F, Langguth O, and Sies H. State of oxidation-reduction and state of binding in the cytosolic NADH-system as disclosed by equilibration with extracellular lactate-pyruvate in hemoglobin-free perfused rat liver. Eur J Biochem 27: 301-317, 1972.
17. Cameron NE, Cotter MA, Basso M, and Hohman TC. Comparison of the effects of inhibitors of aldose reductase and sorbitol dehydrogenase on neurovascular function, nerve conduction and tissue polyol pathway metabolites in streptozotocin-diabetic rats. Diabetologia 40: 271-281, 1997.
18. Chan DC. Mitochondrial fusion and fission in mammals. Annu Rev Cell Devel Biol 22: 79-99, 2006.
19. Chung SS, Ho EC, Lam KS, and Chung SK. Contribution of polyol pathway to diabetes-induced oxidative stress. J Am Soc Nephrol 14: S233-236, 2003.
20. Cusi K, Consoli A, and DeFronzo RA. Metabolic effects of metformin on glucose and lactate metabolism in noninsulin-dependent diabetes mellitus. J Clin Endocrinol Metab 81: 4059-4067, 1996.
21. Davis EJ, Bremer J, and Akerman KE. Thermodynamic aspects of translocation of reducing equivalents by mitochondria. J Biol Chem 255: 2277-2283, 1980.
22. Dawes EA. Quantitative Problems in Biochemistry. Edinburgh & London: Churchill Livingstone, 1972.
23. Farfari S, Schulz V, Corkey B, and Prentki M. Glucose-regulated anaplerosis and cataplerosis in pancreatic beta-cells: possible implication of a pyruvate/citrate shuttle in insulin secretion. Diabetes 49: 718-726, 2000.
24. Fjeld CC, Birdsong WT, and Goodman RH. Differential binding of NAD+ and NADH allows the transcriptional corepressor carboxyl-terminal binding protein to serve as a metabolic sensor. Proc Natl Acad Sci USA 100: 9202-9207, 2003.
25. Fulco M, Schiltz RL, Iezzi S, King MT, Zhao P, Kashiwaya Y, Hoffman E, Veech RL, and Sartorelli V. Sir2 regulates skeletal muscle differentiation as a potential sensor of the redox state. Mol Cell 12: 51-62, 2003.
26. Gao H, Korthuis RJ, and Benoit JN. Effects of reactive oxygen metabolites on norepinephrine-induced vasoconstriction. Free Radic Biol Med 16: 839-843, 1994.
27. Geisen K, Utz R, Grotsch H, Lang HJ, and Nimmesgern H. Sorbitol-accumulating pyrimidine derivatives. Arzneimittelforschung 44: 1032-1043, 1994.
28. Goldberg R, Tewari Y, Bell D, Fazio K, and Anderson E. Thermodynamics of enzyme-catalyzed reactions: Part 1. oxidoreductases. J Phys Chem Ref Data 22: 517-582, 1993.
29. Graymore CN and Towlson MJ. The metabolism of the retina of the normal and alloxan diabetic rat. The levels of oxidised and reduced pyridine nucleotides and the oxidation of the carbon-1 and carbon-6 of glucose. Vision Res 5: 379-389, 1966.
30. Grivennikova VG and Vinogradov AD. Generation of superoxide by the mitochondrial Complex 1. Biochim Biophys Acta 1757: 553-561, 2006.
31. Gumaa KA, McLean P, and Greenbaum AL. Compartmentation in relation to metabolic control in liver. Essays Biochem 7: 39-86, 1971.
32. Guzy RD, Hoyos B, Robin E, Chen H, Liu L, Mansfield KD, Simon MC, Hammerling U, and Schumacker PT. Mitochondrial complex III is required for hypoxia-induced ROS production and cellular oxygen sensing. Cell Melab 1: 401-408, 2005.
33. Guzy RD and Schumacker PT. Oxygen sensing by mitochondria at complex III: the paradox of increased reactive oxygen species during hypoxia. Exp Physiol 91:807-819, 2006.
34. Haigis MC and Guarente LP. Mammalian sirtuins - emerging roles in physiology, aging, and calorie restriction. Genes Dev 20: 2913-2921, 2006.
35. Hall DA, Zhu H, Zhu X, Royce T, Gerstein M, and Snyder M. Regulation of gene expression by a metabolic enzyme. Science 306: 482-484, 2004.
36. Hamada Y, Nakamura J, Naruse K, Komori T, Kato K, Kasuya Y, Nagai R, Horiuchi S, and Hotta N. Epalrestat, an aldose reductase ihibitor, reduces the levels of Nepsilon-(carboxymethyl) lysine protein adducts and their precursors in erythrocytes from diabetic patients. Diabetes Care 23: 1539-1544, 2000.
37. Hansen SH. The role of taurine in diabetes and the development of diabetic complications. Diabetes Metab Res Rev 17: 330-346, 2001.
38. Hanukoglu I and Rapoport R. Routes and regulation of NADPH production in steroidogenic mitochondria. Endocr Res 21: 231-241, 1995.
39. Heyningen R. Formation of polyols by the lens of the rat with 'sugar' cataract. Nature 184: 194-195, 1959.
40. Ho EC, Lam KS, Chen YS, Yip JC, Arvindakshan M, Yamagishi S, Yagihashi S, Oates PJ, Ellery CA, Chung SS, and Chung SK. Aldose reductase-deficient mice are protected from delayed motor nerve conduction velocity, increased c-Jun NH2-terminal kinase activation, depletion of reduced glutathione, increased superoxide accumulation, and DNA damage. Diabetes 55: 1946-1953, 2006.
41. Hotta N, Akanuma Y, Kawamori R, Matsuoka K, Oka Y, Shichiri M, Toyota T, Nakashima M, Yoshimura I, Sakamoto N, and Shigeta Y. Long-term clinical effects of epalrestat, an aldose reductase inhibitor, on diabetic peripheral neuropathy: the 3-year, multicenter, Comparative Aldose Reductase Inhibitor-Diabetes Complications Trial. Diabetes Care 29: 1538-1544, 2006.
42. Houten SM and Auwerx J. PGC-1[alpha]: Turbocharging mitochondria. Cell 119: 5-7, 2004.
43. Hwang YC, Bakr S, Ellery CA, Oates PJ, and Ramasamy R. Sorbitol dehydrogenase: a novel target for adjunctive protection of ischemic myocardium. FASEB J 17: 2331-2333, 2003.
44. Ido Y, Chang K, and Williamson JR. NADH augments blood flow in physiologically activated retina and visual cortex. Proc Natl Acad Sci USA 101: 653-658, 2004.
45. Ido Y, Chang K, Woolsey TA, and Williamson JR. NADH: sensor of blood flow need in brain, muscle, and other tissues. FASEB J 15: 1419-1421, 2001.
46. Ido Y, Ostrow E, L. MB, Oates PJ, and Williamson JR. Decreased motor nerve conduction velocity (MNCV) in diabetic rats is linked to cytosolic reductive stress. Diabetologia (Suppl 1) 40: A33, 1997.
47. Ido Y and Williamson JR. Hyperglycemic cytosolic reductive stress 'pscudohypoxia': implications for diabetic retinopathy. Invest Ophthalmol Vis Sci 38: 1467-1470, 1997.
48. Ii S, Ohta M, Kudo E, Yamaoka T, Tachikawa T, Moritani M, Itakura M, and Yoshimoto K. Redox state-dependent and sorbitol accumulation-independent diabetic albuminuria in mice with transgene-dcrived human aldose reductase and sorbitol dehydrogenase deficiency. Diabetologia 47: 541-548, 2004.
49. Iwata K, Matsuno K, Nishinaka T, Persson C, and Yabe-Nishimura C. Aldose reductase inhibitors improve myocardial reperfusion injury in mice by a dual mechanism. J Pharmacol Sci 102: 37-46, 2006.
50. Kaiserova K, Srivastava S, Hoetker JD, Awe SO, Tang XL, Cai J, and Bhatnagar A. Redox activation of aldose reductase in the ischemic heart. J Biol Chem 281: 15110-15120, 2006.
51. Kaneko M, Bucciarelli L, Hwang YC, Lee L, Yan SF, Schmidt AM, and Ramasamy R. Aldose reductase and AGE-RAGE pathways: key players in myocardial ischemic injury. Ann NY Acad Sci 1043: 702-709, 2005.
52. Kasajima H, Yamagishi S, Sugai S, Yagihashi N, and Yagihashi S. Enhanced in situ expression of aldose reductase in peripheral nerve and renal glomeruli in diabetic patients. Virchows Arch 439: 46-54, 2001.
53. Kelley DE and Mandarino LJ. Hyperglycemia normalizes insulin-stimulated skeletal muscle glucose oxidation and storage in noninsulin-dependent diabetes mellitus. J Clin Invest 86: 1999-2007, 1990.
54. Kim JH, Cho EJ, Kim ST, and Youn HD. CtBP represses p300-mediated transcriptional activation by direct association with its bromodomain. Nat Struct Mol Biol 12: 423-428, 2005.
55. Kinoshita JH, Fukushi S, Kador P, and Merola LO. Aldose reductase in diabetic complications of the eye. Metabolism 28: 462-469, 1979.
56. Krebs HA. The redox state of nicotinamide adenine dinucleotide in the cytoplasm and mitochondria of rat liver. Adv Enzyme Regal 5:409-434, 1967.
57. Kukidome D, Nishikawa T, Sonoda K, Imoto K, Fujisawa K, Yano M, Motoshima H, Taguchi T, Matsumura T, and Araki E. Activation of AMP-activated protein kinase reduces hyperglycemia-induced mitochondrial reactive oxygen species production and promotes mitochondrial biogenesis in human umbilical vein endothelial cells. Diabetes 55: 120-127, 2006.
58. Lagouge M, Argmann C, Gerhart-Hines Z, Meziane H, Lerin C, Daussin F, Messadeq N, Milne J, Lambert P, Elliott P, Geny B, Laakso M, Puigserver P, and Auwerx J. Resveratrol improves mitochondrial function and protects against metabolic disease by activating SIRT1 and PGC-1[alpha]. Cell 127: 1109-1122, 2006.
59. Lakowicz J, Szmacinski H, Nowaczyk K, and Johnson M. Fluorescence lifetime imaging of free and protein-bound NADH. Pros Natl Acad Sci USA 89: 1271-1275, 1992.
60. Lee AY and Cluing SS. Contributions of polyol pathway to oxidative stress in diabetic cataract. FASEB J 13: 23-30, 1999.
61. Lo AC, Cheung AK, Hung VK, Yeung CM, He QY, Chiu JF, Chung SS, and Chung SK. Deletion of aldose reductase leads to protection against cerebral ischemic injury. J Cereb Blood Flow Metab 2007.
62. Lûpez-Lluch G, Hunt N, Jones B, Zhu M, Jamieson H, Hilmer S, Cascajo MV, Allard J, Ingram DK, Navas P, and de Cabo R. Calorie restriction induces mitochondrial biogenesis and bioenergetic efficiency. Proc Natl Acad Sci USA 103: 1768-1773, 2006.
63. MacDonald MJ. Feasibility of a mitochondrial pyruvate malate shuttle in pancreatic islets. J Biol Chem 270: 20051-20058, 1995.
64. Marmorstein R. Dehydrogenases, NAD, and transcription - what's the connection? Structure 10: 1465-1466, 2002.
65. Marmorstein R and Roth SY. Histone acetyltransferases: function, structure, and catalysis. Curr Opin Genet Dev 11: 155-161, 2001.
66. Matsuzaki H, Daitoku H, Hatta M, Aoyama H, Yoshimochi K, and Fukamizu A. Acetylation of Foxol alters its DNA-binding ability and sensitivity to phosphorylation. Proc Natl Acad Sci USA 102: 11278-11283, 2005.
67. McBride HM, Neuspiel M, and Wasiak S. Mitochondria: more than just a powerhouse. Curr Biol 16: R551-560, 2006.
68. McGarry JD and Dobbins RL. Fatty acids, lipotoxicity and insulin secretion. Diabetologia 42: 128-138, 1999.
69. Mintun MA, Vlassenko AG, Rundle MM, and Raichle ME. Increased lactate/pyruvate ratio augments blood flow in physiologically activated human brain. Proc Natl Acad Sci USA 101: 659-664, 2004.
70. Mohazzab HK, Kaminski PM, and Wolin MS. Lactate and PO2 modulate superoxide anion production in bovine cardiac myocytes; potential role of NADH oxidase. Circulation 96: 614-620, 1997.
71. Morrison AD, Clements RS, Jr., and Winegrad AI. Effects of elevated glucose concentrations on the metabolism of the aortic wall. J Clin Invest 51: 3114-3123, 1972.
72. Muller FL, Liu Y, and Van Remmen H. Complex III releases superoxide to both sides of the inner mitochondrial membrane. J Biol Chem 279: 49064-49073, 2004.
73. Murray R, Granner D, Mayes P, and Rodwell V. Harper's Biochemistry. Norwalk: Appleton & Lange, 1993.
74. Nemoto S, Fergusson MM, and Finkel T. SIRT1 Functionally interacts with the metabolic regulator and transcriptional coactivator PGC-1{alpha}. J Biol Chem 280: 16456-16460, 2005.
75. Ng TF, Lee FK, Song ZT, Calcutt NA, Lee AY, Chung SS, and Chung SK. Effects of sorbitol dehydrogenase deficiency on nerve conduction in experimental diabetic mice. Diabetes 47: 961-966, 1998.
76. Nishikawa T, Edelstein D, Du XL, Yamagishi S-I, Matsumura T, Kaneda Y, Yorek MA, Beebe D, Oates PJ, Hammes H-P, Giardino I, and Brownlee M. Normalizing mitochondrial superoxide production blocks three pathways of hyperglycaemic damage. Nature 404: 787-790, 2000.
77. Nisoli E, Clementi E, Paolucci C, Cozzi V, Tonello C, Sciorati C, Bracale R, Valerio A, Francolini M, Moncada S, and Carruba MO. Mitochondrial biogenesis in mammals: the role of endogenous nitric oxide. Science 299: 896-899, 2003.
78. Nyengaard JR, Ido Y, Kilo C, and Williamson JR. Interactions between hyperglycemia and hypoxia: implications for diabetic retinopathy. Diabetes 53: 2931-2938, 2004.
79. Obrosova I, Faller A, Burgan J, Ostrow E, and Williamson JR. Glycolytic pathway, redox state of NAD(P)-couples and energy metabolism in lens in galactose-fed rats: effect of an aldose reductase inhibitor. Curr Eye Res 16: 34-43, 1997.
80. Obrosova I. J. M, Faller A, and Williamson JR. Reductive stress is a very early metabolic imbalance in sciatic nerve in diabetes and galactose-fed rats. Diabetologia 38 (Suppl.): A8, 1995.
81. Obrosova IG, Drel VR, Kumagai AK, Szabo C, Pacher P, and Stevens MJ. Early diabetes-induced biochemical changes in the retina: comparison of rat and mouse models. Diabetologia 49: 2525-2533, 2006.
82. Obrosova IG, Fathallah L, Lang HJ, and Greene DA. Evaluation of a sorbitol dehydrogenase inhibitor on diabetic peripheral nerve metabolism: a prevention study. Diabetologia 42: 1187-1194, 1999.
83. Obrosova IG, Stevens MJ, and Lang HJ. Diabetes-induced changes in retinal NAD-redox status: pharmacological modulation and implications for pathogenesis of diabetic retinopathy. Pharmacology 62: 172-180, 2001.
84. Peuhkurinen KJ, Takala TE, Nuutinen EM, and Hassinen IE. Tricarboxylic acid cycle metabolites during ischemia in isolated perfused rat heart. Am J Physiol Heart Circ Physiol 244: H281-288, 1983.
85. Pioli PA, Hamilton BJ, Connolly JE, Brewer G, and Rigby WFC. Lactate dehydrogenase is an AU-rich element-binding protein that directly interacts with AUF1. J Biol Chem 277: 35738-35745, 2002.
86. Pryor WA and Squadrito GL. The chemistry of peroxynitrite: a product from the reaction of nitric oxide with superoxide. Am J Physiol 268: L699-722, 1995.
87. Ramasamy R, Trueblood N, and Schaefer S. Metabolic effects of aldose reductase inhibition during low-flow ischemia and reperfusion. Am J Physiol 275: H195-203, 1998.
88. Randle PJ, Garland PB, Hales CN, and Newsholme EA. The glucose fatty-acid cycle. Its role in insulin sensitivity and the metabolic disturbances of diabetes mellitus. Lancet 1: 785-789, 1963.
89. Raskin P. The DCCT-finally!! J Diabetes Comp 7: 214-215, 1993.
90. Revollo JR, Grimm AA, and Imai S. The NAD biosynthesis pathway mediated by nicotinamide phosphoribosyltransferase regulates Sir2 activity in mammalian cells. J Biol Chem 279: 50754-50763, 2004.
91. Rodgers JT, Lerin C, Haas W, Gygi SP, Spiegelman BM, and Puigserver P. Nutrient control of glucose homeostasis through a complex of PGC-1alpha and SIRT1. Nature 434: 113-118, 2005.
92. Salway JG. Metabolism at a Glance. Cambridge: Blackwell Science, 1999.
93. Schmidt MT, Smith BC, Jackson MD, and Denu JM. Coenzyme specificity of Sir2 protein deacetylases: implications for physiological regulation. J Biol Chem 279: 40122-40129, 2004.
94. Schmidt RE, Dorsey DA, Beaudet LN, Parvin CA, Yarasheski KE, Smith SR, Williamson JR, Peterson RG, and Oates PJ. A potent sorbitol dehydrogenase inhibitor exacerbates sympathetic autonomic neuropathy in rats with streptozotocin-induced diabetes. Exp Neurol 192: 407-419, 2005.
95. Schmidt RE, Dorsey DA, Beaudet LN, Plurad SB, Parvin CA, Yarasheski KE, Smith SR, Lang HJ, Williamson JR, and Ido Y. Inhibition of sorbitol dehydrogenase exacerbates autonomic neuropathy in rats with streptozotocin- induced diabetes. J Neuropathol Exp Neurol 60: 1153-1169, 2001.
96. Schmidt RE, Dorsey DA, Beaudet LN, Plurad SB, Williamson JR, and Ido Y. Effect of sorbitol dehydrogenase inhibition on experimental diabetic autonomic neuropathy. J Neuropathol Exp Neurol 57: 1175-1189, 1998.
97. Sewalt RG, Gunster MJ, van der Vlag J, Satijn DP, and Otte AP. C-Terminal binding protein is a transcriptional repressor that interacts with a specific class of vertebrate polycomb proteins. Mol Cell Biol 19: 777-787, 1999.
98. Shi Y, Sawada J-I, Sui G, Affar EB, Whetstine JR, Lan F, Ogawa H, Po-Shan Luke M, Nakatani Y, and Shi Y. Coordinated histone modifications mediated by a CtBP co-repressor complex. Nature 422: 735-738, 2003.
99. Sinclair DA. Toward a unified theory of caloric restriction and longevity regulation. Mech Ageing Dev 126: 987-1002, 2005.
100. Sinclair DA and Guarente L. Unlocking the secrets of longevity genes. Sci Am 294: 48-51, 54-47, 2006.
101. Soriano FG, Packer P, Mabley J, Liaudet L, and Szabo C. Rapid reversal of the diabetic endothelial dysfunction by pharmacological inhibition of poly(ADP-ribose) polymerase. Circ Res 89: 684-691, 2001.
102. Soriano FG, Virag L, and Szabo C. Diabetic endothelial dysfunction: role of reactive oxygen and nitrogen species production and poly(ADP-ribose) polymerase activation. J Mol Med 79: 437-448, 2001.
103. Srivastava SK, Ansari NH, Hair GA, Jaspan J, Rao MB, and Das B. Hyperglycemia-induced activation of human erythrocyte aldose reductase and alterations in kinetic properties. Biochimica et Biophysica Acta 870: 302-311, 1986.
104. Stryer L. Biochemistry. New York: WH Freeman and Company, 1995.
105. Sturman JA. Pentose phosphate pathway metabolism by normal and glucose-6-phosphate dehydrogenase-deficient human red cell haemolysates. Clin Chim Acta 18: 245-248, 1967.
106. Tesfaye S. Is epalrestat an effective treatment for diabetic peripheral neuropathy? Nat Clin Pract Endocrinol Metab 3: 84-85, 2007.
107. Tessari P, Nosadini R, Trevisan R, De Kreutzenberg SV, Inchiostro S, Duner E, Biolo G, Marescotti MC, Tiengo A, and Crepaldi G. Defective suppression by insulin of leucine-carbon appearance and oxidation in type 1, insulin-dependent diabetes mellitus. Evidence for insulin resistance involving glucose and amino acid metabolism. J Clin Invest 77: 1797-1804, 1986.
108. Thomas G and Ramwell PW. Xanthine oxidase and endothelium dependent relaxation. Biochem Biophys Res Commun 147: 682-686, 1987.
109. Tilton RG, Baier LD, Harlow JE, Smith SR, Ostrow E, and Williamson JR. Diabetes-induced glomerular dysfunction: links to a more reduced cytosolic ratio of NADH/NAD+. Kidney Int 41: 778-788, 1992.
110. Tilton RG, Chang K, Nyengaard JR, Van den Enden M, Ido Y, and Williamson JR. Inhibition of sorbitol dehydrogenase. Effects on vascular and neural dysfunction in streptozocin-induced diabetic rats. Diabeles 44: 234-242, 1995.
111. Tilton RG, Kawamura T, Chang KC, Ido Y, Bjercke RJ, Stephan CC, Brock TA, and Williamson JR. Vascular dysfunction induced by elevated glucose levels in rats is mediated by vascular endothelial growth factor. J Clin Invest 99: 2192-2202, 1997.
112. Travis SF, Morrison AD, Clements RS Jr., Winegrad AI, and Oski FA. Metabolic alterations in the human erythrocyte produced by increases in glucose concentration. The role of the polyol pathway. J Clin Invest 50: 2104-2112, 1971.
113. Trevisan R, Nosadini R, Avogaro A, Lippe G, Duner E, Fioretto P, Deana R, Tessari P, Tiengo A, Velussi M, and et al. Type 1 diabetes is characterized by insulin resistance not only with regard to glucose, but also to lipid and amino acid metabolism. J Clin Endocrinol Melab 62: 1155-1162, 1986.
114. Turner RC and Holman RR. Lessons from UK prospective diabetes study. Diabetes Res Clin Pract 28: S151-S157, 1995.
115. Van den Enden MK, Nyengaard JR, Ostrow E, Burgan JH, and Williamson JR. Elevated glucose levels increase retinal glycolysis and sorbitol pathway metabolism. Implications for diabetic retinopathy. Invest Ophthalmol Vis Sci 36: 1675-1685, 1995.
116. Vannini P, Marehesini G, Forlani G, Angiolini A, Ciavarella A, Zoli M, and Pisi E. Branched-chain amino acids and alanine as indices of the metabolic control in type 1 (insulin-dependent) and type 2 (non-insulin-dependent) diabetic patients. Diabetologia 22: 217-219, 1982.
117. Varma SD and Kinoshita JH. Sorbitol pathway in diabetic and galactosemic rat lens. Biochimica Biophysica Acta (BBA) - General Subjects 338: 632-640, 1974.
118. Veech RL, Eggleston LV, and Krebs HA. The redox state of free nicotinamide-adenine dinucleotidc phosphate in the cytoplasm of rat liver. Biochem J 115: 609-619, 1969.
119. Vettor R, Lombardi AM, Fabris R, Pagano C, Cusin I, Rohner-Jeanrenaud F, Federspil G, and Jeanrenaud B. Lactate infusion in anesthetized rats produces insulin resistance in heart and skeletal muscles. Metabolism 46: 684-690, 1997.
120. Wei EP, Christman CW, Kontos HA, and Povlishock JT. Effects of oxygen radicals on cerebral arterioles. Am J Physiol 248: H157-162, 1985.
121. Wermuth B, Burgisser H, Bohren K, and Wartburg J-P. Purification and characterization of human-brain aldose reductase. Eur J Biochem 127: 279-284, 1982.
122. Williamson DH, Lund P, and Krebs HA. The redox state of free nicotinamide-adenine dinucleotide in the cytoplasm and mitochondria of rat liver. Biochem J 103: 514-527, 1967.
123. Williamson JR, Chang K, Frangos M, Hasan KS, Ido Y, Kawamura T, Nyengaard JR, van den Enden M, Kilo C, and Tilton RG. Hyperglycemic pseudohypoxia and diabetic complications. Diabetes 42: 801-813, 1993.
124. Williamson JR and Ido Y. Understanding retinal cytosolic reductive stress. Invest Ophthalmol Vis Sci 39: 1295-1296, 1998.
125. Williamson JR, Kilo C, and Ido Y. The role of cytosolic reductive stress in oxidant formation and diabetic complications. Diabetes Res Clin Pract 45: 81-82, 1999.
126. Wolin MS, Ahmad M, and Gupte SA. The sources of oxidative stress in the vessel wall. Kidney Int 67: 1659-1661, 2005.
127. Wolin MS and Belloni FL. Superoxide anion selectively attenuates catecholamine-induced contractile tension in isolated rabbit aorta. Am J Physiol 249: H1127-1133, 1985.
128. Yechoor VK, Patti ME, Ueki K, Laustsen PG, Saccone R, Rauniyar R, and Kahn CR. Distinct pathways of insulin-regulated versus diabetes-regulated gene expression: an in vivo analysis in MIRKO mice. Proc Natl Acad Sci USA 101: 16525-16530, 2004.
129. Yu T, Robotham JL, and Yoon Y. Increased production of reactive oxygen species in hyperglycemic conditions requires dynamic change of mitochondrial morphology. Proc Natl Acad Sci USA 103: 2653-2658, 2006.
130. Zhang Q, Piston DW, and Goodman RH. Regulation of corepressor function by nuclear NADH. Science 295: 1895-1897, 2002.
131. Zhang Q, Wang S-Y, Fleuriel C, Leprince D, Rocheleau JV, Piston DW, and Goodman RH. Metabolic regulation of SIRT1 transcription via a HIC1:CtBP corepressor complex. Proc Natl Acad Sci USA 104: 829-833, 2007.
132. Zhang Q, Wang S-Y, Nottke AC, Rocheleau JV, Piston DW, and Goodman RH. Redox sensor CtBP mediates hypoxia-induced tumor cell migration. Proc Natl Acad Sci USA 103: 9029-9033, 2006.
133. Zheng L, Roeder RG, and Luo Y. S phase activation of the histone H2B promoter by OCA-S, a coactivator complex that contains GAPDH as a key component. Cell 114: 255-266, 2003.